DK3234597T3 - Proteiner af WNT-signalvejen og anvendelser deraf i diagnostik og behandling af hypopigmenteringssygdomme - Google Patents

Proteiner af WNT-signalvejen og anvendelser deraf i diagnostik og behandling af hypopigmenteringssygdomme Download PDF

Info

Publication number
DK3234597T3
DK3234597T3 DK15813367.8T DK15813367T DK3234597T3 DK 3234597 T3 DK3234597 T3 DK 3234597T3 DK 15813367 T DK15813367 T DK 15813367T DK 3234597 T3 DK3234597 T3 DK 3234597T3
Authority
DK
Denmark
Prior art keywords
diagnosis
proteins
treatment
signaling pathway
wnt signaling
Prior art date
Application number
DK15813367.8T
Other languages
English (en)
Inventor
Thierry Passeron
Florence Joly
Original Assignee
Inst Nat Sante Rech Med
Chu De Nice
Univ Cote D'azur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Chu De Nice, Univ Cote D'azur filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3234597T3 publication Critical patent/DK3234597T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/207—Pigmentation disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15813367.8T 2014-12-18 2015-12-16 Proteiner af WNT-signalvejen og anvendelser deraf i diagnostik og behandling af hypopigmenteringssygdomme DK3234597T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14307089 2014-12-18
PCT/EP2015/080066 WO2016097035A1 (en) 2014-12-18 2015-12-16 Proteins of the wnt signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders

Publications (1)

Publication Number Publication Date
DK3234597T3 true DK3234597T3 (da) 2022-02-07

Family

ID=52396377

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15813367.8T DK3234597T3 (da) 2014-12-18 2015-12-16 Proteiner af WNT-signalvejen og anvendelser deraf i diagnostik og behandling af hypopigmenteringssygdomme

Country Status (7)

Country Link
US (2) US10983134B2 (da)
EP (1) EP3234597B1 (da)
DK (1) DK3234597T3 (da)
ES (1) ES2905438T3 (da)
PL (1) PL3234597T3 (da)
PT (1) PT3234597T (da)
WO (1) WO2016097035A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905438T3 (es) * 2014-12-18 2022-04-08 Inst Nat Sante Rech Med Proteínas de la vía de señalización de WNT y usos de las mismas en el diagnóstico y tratamiento de trastornos de hipopigmentación
WO2022151450A1 (zh) * 2021-01-16 2022-07-21 海口仁术皮肤科门诊部有限公司 毛囊黑素细胞干细胞移植术治疗白癜风的技术方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368131B2 (en) * 2003-02-27 2008-05-06 Supernatural Health, Inc. Method and composition for treating hypopigmentation of the hair and skin
DE202004013006U1 (de) 2004-07-15 2004-11-04 Otto Sauer Achsenfabrik Keilberg Bremseinrichtung mit Bremssattelbefestigung
WO2006078886A2 (en) * 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
KR20110130282A (ko) * 2010-05-27 2011-12-05 아주대학교산학협력단 Ｗｉｆ-1 조절을 통한 색소 질환 치료용 조성물
KR102031161B1 (ko) * 2011-10-18 2019-10-14 (주)아모레퍼시픽 피부 미백 물질 스크리닝 시스템
KR20130073069A (ko) 2011-12-23 2013-07-03 현대모비스 주식회사 오디오 이상 유무 자가 진단 가능한 음원 재생 장치 및 그 방법
ES2905438T3 (es) * 2014-12-18 2022-04-08 Inst Nat Sante Rech Med Proteínas de la vía de señalización de WNT y usos de las mismas en el diagnóstico y tratamiento de trastornos de hipopigmentación
WO2016097031A1 (en) * 2014-12-18 2016-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Gsk3b and uses thereof in the diagnostic and treatment of hypopigmentation disorders

Also Published As

Publication number Publication date
US20210190800A1 (en) 2021-06-24
PL3234597T3 (pl) 2022-03-07
PT3234597T (pt) 2022-02-15
EP3234597B1 (en) 2021-11-10
US11650214B2 (en) 2023-05-16
US10983134B2 (en) 2021-04-20
US20180180631A1 (en) 2018-06-28
WO2016097035A1 (en) 2016-06-23
WO2016097035A9 (en) 2017-08-24
ES2905438T3 (es) 2022-04-08
EP3234597A1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
DK3099717T3 (da) Antistofmolekyler med tim-3 og anvendelser deraf
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3656875T3 (da) Ikke-invasiv prænatal diagnostik
DK3227342T4 (da) Proteinøs heterodimer og anvendelse deraf
DK3099172T3 (da) Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3302431T3 (da) Taxanpartikler og anvendelse deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
CL2016002738A1 (es) Variantes del anticuerpo anti-factor d y sus usos
DK3202305T3 (da) Engangsendoskop og system
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3240436T3 (da) Sammensætning indeholdende kitin og fordøjelige proteiner
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3233066T3 (da) Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser
DK3100050T3 (da) Immobiliserede proteiner og anvendelse deraf
DK3417058T3 (da) Sortase-modificerede molekyler og anvendelser deraf
DK2963077T3 (da) Hydrofile blokcopolymere og deraf fremstillede membraner
DK3233105T3 (da) Hidtil ukendt kombination og anvendelse
DK3157522T3 (da) Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3131920T3 (da) Msp-nanoporer og anvendelser deraf
DK3208332T3 (da) Laktaseopløsning og mælk med samme
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier